Moderna, Q4 and MRNA
Pharma giant Moderna (MRNA) is set to release its Q4 2024 results on February 14. MRNA stock has lost about 64% over the past ...
A bill that would ban the use of mRNA vaccines, including for Covid-19, is on its way to the House floor after passing out of ...
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Cells in the body have to move around in order to do their jobs. During development, for instance, cells are distributed to ...
The president announced a major AI investment project, which Oracle Chairman Larry Ellison said could be used to cure cancer.
1d
Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...
Wilmington Savings Fund Society FSB grew its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 295.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 786 shares of the ...
In principle, mRNA vaccines are ideal for health emergencies as they can be quickly mass produced using a template. The problem is that current cell-based template production methods take too long, ...
A research team from POSTECH has developed a biodegradable polymer-based delivery system that efficiently transports mRNA.
The process of translation can be seen as the decoding of instructions for making proteins, involving mRNA in transcription as well as tRNA. But where does translation take place within a cell?
Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback